ArticleCurrent chemical genomics2011
Drug discovery toward antagonists of methyl-lysine binding proteins.
Article in Current chemical genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Getting a handle on chemical probes of chomatin readers.Future medicinal chemistry · 2021Article
- Targeting epigenetics for cancer therapy.Archives of pharmacal research · 2019Review
- Target class drug discovery.Nature chemical biology · 2017Article
- Developing Spindlin1 small-molecule inhibitors by using protein microarrays.Nature chemical biology · 2017Article
- Histone peptide microarray screen of chromo and Tudor domains defines new histone lysine methylation interactions.Epigenetics & chromatin · 2017Article
- The L3MBTL3 Methyl-Lysine Reader Domain Functions As a Dimer.ACS chemical biology · 2016Article
- A Structural Perspective on Readout of Epigenetic Histone and DNA Methylation Marks.Cold Spring Harbor perspectives in biology · 2016Review
- Targeting epigenetic regulations in cancer.Acta biochimica et biophysica Sinica · 2016Review
- Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.Journal of medicinal chemistry · 2013Article
- Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery.ACS chemical biology · 2013Article
- Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules.Molecular pharmacology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The recognition of methyl-lysine and -arginine residues on both histone and other proteins by specific "reader" elements is important for chromatin regulation, gene expression, and control of cell-cycle progression. Recently the crucial role of these reader proteins in cancer development and dedifferentiation has emerged, owing to the increased interest among the scientific community. The methyl-lysine and -arginine readers are a large and very diverse set of effector proteins and targeting them with small molecule probes in drug discovery will inevitably require a detailed understanding of their structural biology and mechanism of binding. In the following review, the critical elements of methyl-lysine and -arginine recognition will be summarized with respect to each protein family and initial results in assay development, probe design, and drug discovery will be highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.